Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | GCGR | P47871 | 1/20 | 0.30 |
| ▸ | GIPR | P48546 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6531938 | 0.93 | NPC1 (0.31) | MAPK14HPGDSMN1; SMN2L3MBTL1NPC1 | |
| Trifluoroacetic Acid SCHEMBL4809541 | 0.88 | MAPT (0.35) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4809310 | 0.88 | MEN1 (0.35) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4802588 | 0.87 | MEN1 (0.35) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4809992 | 0.86 | ENPP2 (0.41) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4809932 | 0.86 | MAPK14 (0.35) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4812018 | 0.85 | NPC1 (0.35) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4812613 | 0.84 | MAPK14 (0.36) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL4805867 | 0.83 | MAPT (0.38) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4806911 | 0.83 | MEN1 (0.36) | MAPK14MEN1HPGDKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381734-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-7157585-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2007-01-02 | — | — | US | disclosed |
| EP-1294691-B1 | SERINE PROTEASE INHIBITORS | TULARIK LTD (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-7074934-B2 | An aromatic alkylamino compound containing a lipophilic group useful as antithrombotic agent as well as treats asthma | TULARIK LIMITED (GB) | 2006-07-11 | — | — | US | disclosed |
| US-7067516-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-20050267173-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-12-01 | — | — | US | disclosed |
| US-20050215587-A1 | Serine protease inhibitors | LIVELY SARAH E | 2005-09-29 | — | — | US | disclosed |
| US-6916957-B2 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2005-07-12 | — | — | US | disclosed |
| US-20040116439-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2004-06-17 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215587-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | MAPK14 3086/4885MEN1 2767/4885HPGD 807/4885 |
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | MAPK14 3700/4885MEN1 2414/4885HPGD 313/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | MAPK14 3266/4885MEN1 2794/4885HPGD 1054/4885 |
| US-20050267173-A1 | Serine protease inhibitors | PRSS1, TPSAB1, CMA1 | MAPK14 3086/4885MEN1 2767/4885HPGD 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.